Challenging quarter across key segments

Company

12 Aug 2024 | 5 Min Read

Biocon's financials and valuations are detailed for FY24, FY25E, and FY26E.

The company's sales, EBITDA, adjusted PAT, and margins are provided.

The shareholding pattern, CMP, and TP are mentioned.

The company's performance in 1QFY25 is discussed, including sales, margins, and EBITDA.

The management's commentary and future outlook for the company are highlighted.

The valuation and view of the company are reiterated as neutral.